Organization
Aichi Cancer Center Hospital, Nagoya, Japan
6 abstracts
Abstract
A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.Org: National Cancer Center Hospital East, Chiba, Japan, Samsung Medical Center, Seoul, seoul, South Korea, NEXT Oncology, San Antonio, TX, National Cancer Center Hospital, Tokyo, Japan, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
ctDNA monitoring for breast cancer at high risk of recurrence: Interim analysis of JCOG1204A1.Org: Department of General Internal Medicine, National Cancer Center Hospital East, Kashiwa, Japan, Breast Medical Oncology Department, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan, National Defense Medical College Hospital, Tokorozawa, Japan, Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan, Department of Breast Care, Saitama Medical Center, Saitama, Japan,
Abstract
Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.Org: Dana-Farber Cancer Institute, University of Wisconsin, University of California Irvine, University of Colorado Denver Department of Radiation Oncology, Perlmutter Cancer Center, NYU Langone Health,
Abstract
Efficacy and safety of combination therapy with binimetinib, encorafenib, and cetuximab for BRAF non-V600E mutated metastatic colorectal cancer: Results from a phase 2 BIG BANG trial (EPOC1703).Org: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Japan, Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan, Aichi Cancer Center Hospital, Nagoya, Japan, Department of Gastrointestinal and Medical Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan,
Abstract
Comprehensive genomic profiling before the first-line setting versus after the completion of standard of care in patients with previously untreated advanced solid tumors: The prospective FIRST-Dx study.Org: Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto University Hospital, Kyoto, Japan, Department of Next-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, The University of Tokyo Hospital, Tokyo, Japan, Tokyo Medical and Dental University, Bunkyo-Ku, Japan,
Abstract
Impact of acute kidney injury on overall survival in postoperative patients with head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of a phase II/III trial of JCOG1008.Org: Kobe University Hospital, Kobe, Hyogo, Japan, National Cancer Center Hospital East, Kashiwa, Chiba, Japan, Aichi Cancer Center Hospital, Nagoya, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Jichi Medical University, Shimotsuke-Shi, TOCHIGI-KEN, Japan,